No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial

Kjær TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL · The Journal of Clinical Endocrinology and Metabolism

NULL, with a signal in the wrong direction. Neither dose lowered hs-CRP, IL-6 or suPAR, and inflammatory gene expression in fat and muscle biopsies was unchanged, as were blood pressure, body composition, liver and muscle lipid, and glucose and lipid metabolism. The 1,000 mg arm significantly raised total cholesterol (p<0.002), LDL cholesterol (p<0.006) and fructosamine (p<0.013) versus placebo.

Population

Community-dwelling middle-aged men with metabolic syndrome, mean age 49.5, mean BMI 33.8

Intervention

Resveratrol 1,000 mg/day or 150 mg/day for 16 weeks

Comparator

Placebo

Limitations

Men only, 16 weeks, one centre. The largest and longest independent metabolic trial of resveratrol, in exactly the population its mechanism predicts should respond.